Skip to main content

Table 2 Demographic, clinical, treatment and radiographic characteristics of the patients included in the csDMARD-to-TNFI and TNFI cohorts

From: Establishment of age- and sex-adjusted reference data for hand bone mass and investigation of hand bone loss in patients with rheumatoid arthritis treated in clinical practice: an observational study from the DANBIO registry and the Copenhagen Osteoarthritis Study

 

csDMARD-to-TNFI cohort

TNFI cohort

Patients with radiographs unsuitable for DXR analysis

 

Time point

Pre-baseline

Baseline

Follow-up

Baseline

Follow-up

Baseline

p valuea

No. of patients

135

135

135

350

350

580

 

Age (years)

55 (44–62)

57 (47–64)

59 (48–65)

56.5 (47–64)

58 (48–66)

57 (49–64)

0.44*

Women (%)

85

85

85

79

79

75

0.08**

Disease duration (years)

4.5 (1–10)

6 (4–12)

8 (5–14)

8 (4–14)

10 (6–15)

10 (5–18)

0.004 *

DAS28

4.3 (3.0–5.3)

5.3 (4.4–6.1)

3.1 (2.2–3.9)

5.3 (4.5–6.1)

3.0 (2.1–4.0)

5.4 (4.7–6.2)

0.24*

CRP (mg/l)

16 (8–33)

18 (8–40)

8 (4–14)

17 (8–35)

8 (3–14)

19 (8–42)

0.09*

IgM-RF positivity (%)

71

71

71

76

76

79

0.77**

Current smokers (%)

36

35

30

34

32

37

0.25**

HAQ score

NA

1.250 (0.750–1.750)

0.825 (0.250–1.375)

1.250 (0.750–1.750)

0.875 (0.250–1.375)

0.875 (0.250–1.500)

<0.001 *

Previous csDMARDs (n)

NA

3 (3–4)

–

3 (2–4)

–

3 (2–4)

0.26*

Length of TNFI period (days)

–

–

574 (405–759)

–

511 (381–695)

538 (397–761)

0.03 *

Concomitant MTX (%)

93

83

74

78

72

75

0.32**

Corticosteroid treatment (%)

–

88c

76d

71c

64d

57d

0.03 **

Prednisolone dosage (mg/day)b

–

1.32 (0.4–5.2)c

1.33 (0.4–3.8)d

1.8 (0.5–5.1)c

2.0 (0.5–4.6)d

2.7 (0.6–5.6)d

0.02 *

Type of TNFI (n (%))

       

INF

 

101 (75)

 

218 (62)

ETA

 

17 (12)

 

68 (20)

ADA

 

18 (13)

 

64 (18)

Treatment at follow-up (n (%))

       

On first TNFI

  

79 (59)

 

216 (62)

  

Switched from first TNFI

  

38 (27)

94 (27)

Withdrawn from TNFI

  

18 (14)

40 (11)

Sharp score (TSS units)

6 (0–21)

10 (1–29)

12 (2–31)

11 (2–34)

12 (3–35)

17 (3–53)

0.001 *

Sharp score (TSS units) (mean (SD))

16 (22)

19 (24)

20 (24.6)

22 (27)

23 (27)

36 (45)

0.001 ***

Erosive disease (%)

70

76

77

81

81

83

0.55**

DXR-BMD (g/cm2) (mean (SD))

0.529 (0.09)

0.506 (0.10)

0.495 (0.10)

0.502 (0.10)

0.490 (0.10)

NA

 
  1. aComparing TNFI cohort with the cohort of patients with radiographs unsuitable for DXR (values in bold are significant)
  2. bAll administered corticosteroids (peroral, intra-articular and intramuscular) were converted to a corresponding daily dosage of prednisolone in patients who had received corticosteroids at least once
  3. cIn the csDMARD period
  4. d In the TNFI period. Medians (interquartile range) are presented unless otherwise indicated.
  5. *Mann-Whitney
  6. **Chi-square
  7. ***Students t-test
  8. ADA Adalimumab, CRP C-reactive protein, csDMARD Conventional synthetic disease-modifying anti-rheumatic drug, DAS28 Disease activity score in 28 joints based on three variables including CRP, DXR Digital x-ray radiogrammetry, DXR-BMD Bone mineral density measured by digital x-ray radiogrammetry, ETA Etanercept, HAQ Health assessment questionnaire, IgM-RF Immunoglobulin M rheumatoid factor, INF Infliximab, NA not available, SD Standard deviation, TSS Total Sharp Score, MTX Methotrexate, TNFI Tumour necrosis factor inhibitor
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us